Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292


SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

05/09/2012 | 07:16pm US/Eastern

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043;

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
React to this article
Latest news on ASTRAZENECA PLC
1d ago AstraZeneca, Ranbaxy fail to end US trial
1d ago AMGEN : And AstraZeneca Announce Positive Results From Third And Final Pivotal P..
1d ago ASTRAZENECA : MHRA -Regulator helps to create new cancer medicine facility
1d ago ASTRAZENECA : ABPI and BIA Welcomes Publication of Case Study Showcasing Benefit..
1d ago ASTRAZENECA : Amgen and AstraZeneca announce positive results from third and fin..
1d ago ASTRAZENECA : Regulator Helps to Create New Cancer Medicine Facility
2d ago ASTRAZENECA : Positive results from brodalumab phase iii study
2d ago ASTRAZENECA : Amgen, AstraZeneca Get Positive Results From Brodalumab Phase 3 St..
3d agoDJJefferies Bumps Up Against Big Rivals as It Looks to Expand
3d ago ASTRAZENECA : Amgen and AstraZeneca announce positive results from third and fin..
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes